[go: up one dir, main page]

MX2018002068A - Purificacion de fkpa y usos de la misma para producir polipeptidos recombinantes. - Google Patents

Purificacion de fkpa y usos de la misma para producir polipeptidos recombinantes.

Info

Publication number
MX2018002068A
MX2018002068A MX2018002068A MX2018002068A MX2018002068A MX 2018002068 A MX2018002068 A MX 2018002068A MX 2018002068 A MX2018002068 A MX 2018002068A MX 2018002068 A MX2018002068 A MX 2018002068A MX 2018002068 A MX2018002068 A MX 2018002068A
Authority
MX
Mexico
Prior art keywords
fkpa
polypeptides
methods
purification
multispecific antibodies
Prior art date
Application number
MX2018002068A
Other languages
English (en)
Inventor
B Fong Chris
A Mckay Patrick
Ladiwala Asif
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2018002068A publication Critical patent/MX2018002068A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona métodos para producir polipéptidos de peptidil-prolil cis/trans isomerasa del tipo FKBP (FkpA) con niveles de pureza muy elevados. También se proporciona FkpA ultrapura y métodos para utilizarla, por ejemplo, para uso en inmunoanálisis para mostrar la eliminación de FkpA de productos biológicos producidos en bacterias. Además, la presente invención proporciona métodos para purificar polipéptidos (por ejemplo, anticuerpos multiespecíficos) producidos en bacterias que sobreexpresan una o más chaperonas. Los métodos incluyen cromatografía de afinidad, cromatografía de modo mixto y cromatografía de interacción hidrófoba. En algunos aspectos, la invención proporciona composiciones de polipéptidos (por ejemplo, anticuerpos multiespecíficos) que están esencialmente libres de impurezas específicas del producto.
MX2018002068A 2015-08-20 2016-08-19 Purificacion de fkpa y usos de la misma para producir polipeptidos recombinantes. MX2018002068A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562207910P 2015-08-20 2015-08-20
US201562207908P 2015-08-20 2015-08-20
US201562210378P 2015-08-26 2015-08-26
PCT/US2016/047912 WO2017031476A2 (en) 2015-08-20 2016-08-19 Purification of fkpa and uses thereof for producing recombinant polypeptides

Publications (1)

Publication Number Publication Date
MX2018002068A true MX2018002068A (es) 2018-06-06

Family

ID=58052052

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002068A MX2018002068A (es) 2015-08-20 2016-08-19 Purificacion de fkpa y usos de la misma para producir polipeptidos recombinantes.

Country Status (13)

Country Link
US (1) US20180327446A1 (es)
EP (1) EP3337819B1 (es)
JP (2) JP7091238B2 (es)
KR (1) KR20180048731A (es)
CN (1) CN108473558A (es)
AU (1) AU2016308383A1 (es)
BR (1) BR112018003127A2 (es)
CA (1) CA2995385A1 (es)
HK (1) HK1259368A1 (es)
IL (2) IL257400A (es)
MX (1) MX2018002068A (es)
TW (1) TW201718623A (es)
WO (1) WO2017031476A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
SG11202003907WA (en) 2017-12-14 2020-05-28 Flodesign Sonics Inc Acoustic transducer drive and controller
ES2905105T3 (es) * 2017-12-29 2022-04-07 Hoffmann La Roche Procedimiento para proporcionar una composición de proteína PEGilada
US12208142B2 (en) 2017-12-29 2025-01-28 Hoffmann-La Roche Inc. Process for providing PEGylated protein composition
AU2019228377B2 (en) 2018-02-27 2023-02-23 Pfizer Inc. Antibody purification
EA202092223A1 (ru) * 2018-03-21 2021-02-10 Баксалта Инкорпорейтед Разделение vwf и пропептида vwf хроматографическими методами
US11453883B2 (en) 2018-04-05 2022-09-27 Bio-Rad Abd Serotec Gmbh Display systems for proteins of interest
EP3856347A1 (en) * 2018-09-25 2021-08-04 Ichnos Sciences SA Antibody quantification in biological samples
CN114409798A (zh) * 2019-02-14 2022-04-29 美勒斯公司 制备包含两种或更多种抗体的组合物
WO2020188350A1 (en) * 2019-03-18 2020-09-24 Bio-Rad Abd Serotec Gmbh Protection of spytag-containing periplasmic fusion proteins from protease tsp and ompt degradation
AU2020268896B2 (en) 2019-05-03 2024-11-28 F. Hoffmann-La Roche Ag Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform
CA3162365A1 (en) * 2019-12-20 2021-06-24 Merck Sharp & Dohme Llc Purified compositions of enteroviruses and methods of purification with glutathione affinity chromatography
JP2023515485A (ja) * 2020-02-21 2023-04-13 バイオジェン・エムエイ・インコーポレイテッド 限外濾過／透析濾過を用いたオリゴヌクレオチド組成物の調製方法
WO2021181417A1 (en) * 2020-03-11 2021-09-16 Dr. Reddy's Laboratories Limited METHOD OF PURIFYING AN Fc-FUSION PROTEIN
CA3233419A1 (en) * 2021-09-28 2023-04-06 Kashiv Biosciences, Llc An improved process for purification of protein
WO2023094282A1 (en) * 2021-11-25 2023-06-01 F. Hoffmann-La Roche Ag Quantification of low amounts of antibody sideproducts

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4309656B2 (ja) * 2000-12-14 2009-08-05 ジェネンテック・インコーポレーテッド 原核生物で生成させた抗体とその用途
JP2011519911A (ja) * 2008-05-05 2011-07-14 ノヴィミュンヌ エスア 抗ｉｌ１７ａ／ｉｌ−１７ｆ交差反応抗体及びその使用方法
TW201024318A (en) * 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
TWI515202B (zh) * 2009-10-20 2016-01-01 艾伯維有限公司 利用蛋白質ａ親和性層析進行抗ｉｌ－１３抗體之分離及純化
US9096648B2 (en) * 2011-08-19 2015-08-04 Emd Millipore Corporation Methods of reducing level of one or more impurities in a sample during protein purification
PT2791176T (pt) * 2011-12-15 2018-11-05 Prestige Biopharma Pte Ltd Um método de purificação de anticorpos
JP2015508994A (ja) * 2011-12-30 2015-03-26 アッヴィ・インコーポレイテッド Ｉｌ−１３および／またはｉｌ−１７に対する二重可変ドメイン免疫グロブリン
EA030551B1 (ru) * 2013-01-09 2018-08-31 Шир Хьюман Дженетик Терапис, Инк. Способы очистки арилсульфатазы а
HK1220919A1 (zh) * 2013-04-05 2017-05-19 F. Hoffmann-La Roche Ag 抗il-4抗体和双特异性抗体及其用途
EP2986731B1 (en) * 2013-04-19 2022-05-18 Sutro Biopharma, Inc. Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones
EP3036253B1 (en) * 2013-08-19 2020-09-23 F. Hoffmann-La Roche AG Separation of bispecific antibodies and bispecific antibody production side products using hydroxyapatite chromatography
MY193481A (en) * 2013-09-13 2022-10-17 Genentech Inc Method and compositions comprising purified recombinant polypeptides
WO2015070069A1 (en) * 2013-11-07 2015-05-14 Abbvie Inc. Isolation and purification of dvd-igs
WO2015127405A2 (en) * 2014-02-21 2015-08-27 Genentech, Inc. Anti-il-13/il-17 bispecific antibodies and uses thereof

Also Published As

Publication number Publication date
JP7091238B2 (ja) 2022-06-27
TW201718623A (zh) 2017-06-01
CN108473558A (zh) 2018-08-31
JP2018533355A (ja) 2018-11-15
WO2017031476A2 (en) 2017-02-23
WO2017031476A3 (en) 2017-04-13
EP3337819B1 (en) 2024-02-21
KR20180048731A (ko) 2018-05-10
HK1259368A1 (zh) 2019-11-29
JP2022062046A (ja) 2022-04-19
AU2016308383A1 (en) 2018-03-15
IL288205A (en) 2022-01-01
BR112018003127A2 (pt) 2018-09-25
EP3337819C0 (en) 2024-02-21
EP3337819A2 (en) 2018-06-27
IL257400A (en) 2018-04-30
CA2995385A1 (en) 2017-02-23
US20180327446A1 (en) 2018-11-15

Similar Documents

Publication Publication Date Title
MX2018002068A (es) Purificacion de fkpa y usos de la misma para producir polipeptidos recombinantes.
AU2017286676A8 (en) Purification of multispecific antibodies
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
ZA202308519B (en) Anti-vegf protein compositions and methods for producing the same
WO2020039321A3 (en) Anti-gdf15 antibodies, compositions and methods of use
HK1206755A1 (en) Low acidic species compositions and methods for producing and using the same
WO2016033225A3 (en) Antibodies, compositions, and uses
WO2016061389A3 (en) Anti-alpha-synuclein antibodies and methods of use
NZ737796A (en) Anti-tau antibodies and methods of use
EP4516319A3 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
PH12016502482A1 (en) Process for the purification of tnfr:fc fusion protein
MX2020010724A (es) Metodos para preparar composiciones proteicas estables.
EA201500943A1 (ru) Составы для мобилизации, хоуминга, размножения и дифференцировки стволовых клеток и способы применения составов
MX392069B (es) Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
NZ760847A (en) Purified 2,5-furandicarboxylic acid pathway products
MX2021000153A (es) Dsba y dsbc ultrapurificado y métodos para elaborarlos y utilizarlos.
WO2016161415A3 (en) Tnfrsf14/ hvem proteins and methods of use thereof
WO2016033437A3 (en) Polyethers, polyamines, polythioethers, and methods for making same
EA201990998A1 (ru) Фармацевтические составы и способы их получения
EA201792366A1 (ru) Способ разделения белка и прочих примесей и капсульных полисахаридов микроорганизмов
MY189854A (en) Method for protein purification
WO2017079443A8 (en) Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
MY183011A (en) Novel purification process of gonadotropin
SG10201805890QA (en) Compositions and methods for treatment of abnormal cell growth
WO2019234614A3 (en) A process for the separation and purification of phycobiliproteins